Skip to main content
TipRanks
Go Ultimate75% OFF

Fresenius SE & Co (FREA) AI Stock Analysis

0 Followers
DE:FREA

Fresenius SE & Co

(Frankfurt:FREA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Broad-based growth and margin expansionBroad-based revenue growth and double-digit EBIT expansion indicate improving operating performance across the portfolio rather than reliance on a single business. Higher margins and raised full-year targets strengthen earnings durability and support reinvestment over the next several quarters.
Negative Factors
Tyenne supply and formulary pressureFormulary deterioration can reduce access to patients and weaken product economics, while supply constraints prevent Fresenius from fully converting strong demand into revenue. Together, these issues may limit near-term biopharma growth and delay operating leverage.

Fresenius SE & Co (FREA) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%DE:FREA+18.03%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 133.60B
Dividend Yield
1.93%
Average Volume (3M)
185
Price to Earnings (P/E)
19.1
Beta (1Y)
1.04
Revenue Growth
6.52%
EPS Growth
35.52%
Country
Germany
Employees
178,394
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

Fresenius SE & Co Business Overview & Revenue Model

Company Description

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius...

Fresenius SE & Co Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:10.92%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentPositive

The call was strongly positive, with broad-based organic growth, double-digit earnings growth, higher margins, improved cash generation, stronger returns, maintained leverage and raised full-year guidance. Fresenius also reported significant progress in biopharma, MedTech, Nutrition, hospital operations and digital health. The main challenges were Tyenne supply constraints and formulary changes, Nutrition-related supply issues in China, Pharma pricing and volume pressure, Melrose Park remediation, higher planned R&D investment and weaker Q4 phasing at Helios. These issues were explicitly discussed but did not outweigh the operational improvements and upgraded outlook.

Positive Updates

Improved Full-Year Core EPS Guidance
Fresenius raised its full-year core EPS growth outlook and now expects growth in the upper half of the 10% to 15% range at constant currency.

Negative Updates

Tyenne Formulary Downgrade and Supply Constraints
Following UNH Optum formulary changes, Tyenne moved from preferred to nonpreferred status. Fresenius said U.S. demand continues to exceed current supply and that the company remains constrained despite securing additional supply and expanding capacity. U.S. market volumes increased 45% year-over-year.

Company Guidance

Fresenius now expects full-year core EPS growth in the upper half of its 10% to 15% guidance range at constant currency, group EBIT margin above 11.5%, full-year interest expense below EUR 300 million, and a tax rate between 24% to 25%; if exchange rates remain at the spot rate of 30th September, it expects no material impact on reported revenue, EBIT or net income for the full year. Kabi’s full-year EBIT margin indication remains 16.5% to 17%, its structural growth band remains applicable, and Nutrition is expected to have an improved growth trajectory for the fourth quarter; Helios overall as a segment is expected to deliver EBIT growth in 2027. The 2030 ambition to double biopharma revenue at an EBIT margin of around 20% remains unchanged, while the self-imposed leverage corridor of 2.5 to 3x remains unchanged.

Fresenius SE & Co Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:FREA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
THCTHC87Outperform$22.76B8.2460.60%―6.23%136.09%
OPCHOPCH72Outperform$4.74B22.7716.36%―4.01%9.94%
FMSFMS66Neutral$11.75B13.416.34%3.92%4.27%26.14%
HCAHCA64Neutral$104.25B16.49-100.45%0.61%5.82%16.59%
DVADVA62Neutral$10.98B13.40-133.21%―6.38%36.05%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

0%50%100%DE:FREAOPCHDVAFMSHCATHCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:FREA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:FREAFresenius Se13.201.4312.12%
OPCHOption Care Health Inc31.653.5412.59%
DVADaVita Inc.174.5657.2948.85%
FMSFresenius Medical Care22.03-0.36-1.63%
HCAHca Healthcare499.0525.195.32%
THCTenet Healthcare Corp.286.0393.6348.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.